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were sourced from the literature. Both costs and outcomes were discounted at 
5%. Results: Incremental costs, QALYs and ICERs for canagliflozin vs. sitagliptin 
were € 1,360, 0.059 QALYs and € 23,118 per QALY, respectively, in dual therapy; € 108, 
0.093 QALYs and € 1,172 per QALY, respectively, in triple therapy; and € 550, 0.068 
QALYs and € 8,047 per QALY, respectively, in add-on to insulin. In all three scenarios, 
canagliflozin was cost-effective using the acceptable willingness-to-pay threshold in 
Ireland. Sensitivity analyses suggest that these results are robust. ConClusions: 
These simulations suggest that the use of canagliflozin in patients in need of addi-
tional glycaemic control in dual, triple and add-on to insulin lines of therapy is a 
more efficient use of health care funds than the use of sitagliptin in the Irish setting.
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objeCtives: Canagliflozin is a novel oral agent for the treatment of T2DM that 
inhibits sodium-glucose co-transporter 2 (SGLT2), a mechanism that is comple-
mentary to other anti-hyperglycaemic drug classes, including insulin. SGLT2 
inhibition leads to inhibition of glucose reabsorption and urinary glucose excre-
tion, thereby reducing blood glucose, weight, and blood pressure. An economic 
(cost-effectiveness) evaluation of new technologies versus routine care is required 
prior to uptake in Ireland to ensure good value-for-money. This study evaluates 
the cost-effectiveness of canagliflozin compared to liraglutide – a currently reim-
bursed and routinely used glucagon-like peptide 1 (GLP-1) agonist – as dual therapy 
in combination with metformin from the payer perspective in the Irish health 
care setting. Methods: The Economic and Health Outcomes Model of T2DM 
(ECHO-T2DM) [using updated UKPDS 82 mortality and risk equations] was used 
to simulate 40-year costs and outcomes associated with canagliflozin (100mg 
titrated to 300mg in patients requiring tighter glycaemic control) compared to 
liraglutide 1.2mg. Patient characteristics were sourced from canagliflozin RCTs 
in patients uncontrolled on metformin monotherapy and treatment effects were 
obtained from a network meta-analysis. The costs of treatments and outcomes 
were localised and inflated to 2013 values where possible. Utilities were sourced 
from the literature. Costs and outcomes were discounted at 5% annually. Results: 
In the base case, canagliflozin was associated with incremental cost savings of 
€ 3,382 compared to liraglutide 1.2mg. It was also associated with a 0.022 more life 
years and 0.020 more quality adjusted life years (QALYs), suggesting that cana-
gliflozin dominates liraglutide. Results were driven by lower acquisition costs for 
canagliflozin. Sensitivity analyses indicated that the dominance observed was 
robust. ConClusions: In these simulations, canagliflozin dominated liraglutide 
1.2mg in dual therapy (add-on to metformin) in the Irish setting. These results 
suggest that canagliflozin represents good ‘value for money’ in treating these 
patients, compared to a routinely used GLP-1 agonist.
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objeCtives: Canagliflozin is a novel drug for treatment of diabetes belonging to the 
drug class known as sodium glucose co-transporter 2 (SGLT2) inhibitors. To evalu-
ate the cost-effectiveness of canagliflozin in dual therapy (add-on to metformin) 
compared to sitagliptin and sulfonylurea (SU), in triple therapy (add on to metformin 
and SU) compared to sitagliptin and as add-on to insulin versus placebo. Methods: 
The IMS CORE Diabetes Model was used to evaluate the cost-effectiveness of cana-
gliflozin (using a weighted average of 80/20 for the 100 mg and 300 mg dosage, 
respectively) versus the aforementioned comparators using Norwegian-specific 
data, where available. Results: In dual therapy, as add-on to metformin versus 
sitagliptin, canagliflozin appears to dominate sitagliptin with average cost sav-
ings of 606 NOK and an average QALY gain of 0.030 and as add on to metformin 
canagliflozin is cost-effective versus SU, with an incremental cost-effectiveness 
ratio (ICER) of 79,309 NOK and an incremental cost of 5,757.80 NOK and an aver-
age QALY gain of 0.0726. As add on to insulin canagliflozin appears to dominate 
placebo with an incremental cost saving of 13,506 NOK and an incremental QALY 
of 0.080. In triple therapy as add on to metformin and SU canagliflozin appears to 
dominate sitagliptin with average cost savings of 556 NOK and an average QALY 
gain of 0.021. ConClusions: Canagliflozin is associated with cost savings and 
QALY gain compared to sitagliptin in dual therapy as add-on to metformin, and in 
triple therapy as add on to metformin and SU. Canagliflozin will be a cost-effective 
alternative to SU in dual therapy as add on to metformin. Adding canagliflozin to 
insulin will be cost-effective compared with placebo i. e. it is cost-effective to add 
canagliflozin treatment rather than not.
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objeCtives: To project the long-term costs and outcomes of sensor-augmented 
pump (SAP) with low glucose suspend (LGS) versus insulin pump alone (CSII) for 
the treatment of hypo-prone Type 1 diabetes in Slovakia. Methods: The CORE 
Diabetes Model is a peer-reviewed, validated model, which employs standard 
showed that at a willingness-to-pay threshold of £20,000 per QALY, the proposed 
treatment pathway had a 100% probability to be cost-effective. ConClusions: 
The proposed alternative treatment sequence was shown to be a cost-effective 
treatment option in patients inadequately controlled with metformin alone within 
established UK cost-effectiveness thresholds.
PDB74
CosT-effeCTiveness analysis of liraglUTiDe versUs siTagliPTin or 
exenaTiDe in PaTienTs WiTh inaDeqUaTely ConTrolleD TyPe 2 DiaBeTes 
on oral anTiDiaBeTiC DrUgs in greeCe
Tzanetakos C.1, Melidonis A.2, Verras C.2, Kourlaba G.3, Maniadakis N.1
1National School of Public Health, Athens, Greece, 2Tzanio General Hospital, Piraeus, Greece, 
3National and Kapodistrian University of Athens School of Medicine, Athens, Greece
objeCtives: To evaluate the long-term cost-effectiveness of liraglutide versus sit-
agliptin or exenatide, added to oral antidiabetic drug mono- or combination ther-
apy respectively, in patients with Type 2 diabetes in Greece. Methods: The CORE 
Diabetes Model, a validated computer simulation model developed to determine 
the long-term health and economic outcomes of interventions in Type 2 diabe-
tes, was adapted to the Greek health care setting. Patient and intervention effects 
data were gathered from a clinical trial comparing liraglutide 1.2mg once daily 
vs. sitagliptin 100mg once daily, both combined with metformin, and a clinical 
trial comparing liraglutide 1.8mg once daily vs. exenatide 10μ g twice daily, both as 
add-on to metformin, glimepiride or both. Direct costs were reported in 2013 Euros 
and calculated based on published and local sources. All future outcomes were 
discounted at 3.5% per annum, and the analysis was conducted from the perspec-
tive of a third-party payer in Greece. Results: Over a patient’s lifetime, treatment 
with liraglutide 1.2mg vs. sitagliptin drove a mean increase in discounted life expec-
tancy of 0.13 (SD 0.23) years and in discounted quality-adjusted life expectancy 
of 0.19 (0.16) quality-adjusted life years (QALYs), whereas therapy with liraglutide 
1.8mg vs. exenatide yielded increases of 0.14 (0.23) years and 0.19 (0.16) QALYs 
respectively. As regards lifetime direct costs, liraglutide 1.2mg resulted in greater 
costs of € 2797 (€ 1468) versus sitagliptin, and so did liraglutide 1.8mg compared 
with exenatide (€ 1302 [€ 1492]). Liraglutide 1.2 and 1.8mg doses were associated 
with incremental cost effectiveness ratios of € 15101 and € 6818 per QALY gained, 
respectively. ConClusions: Liraglutide is likely to be a cost-effective option for 
the treatment of Type 2 diabetes in a Greek setting.
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objeCtives: Canagliflozin is a novel drug for treatment of diabetes belonging to 
the drug class known as sodium glucose co-transporter–2 (SGLT-2) inhibitors. To 
evaluate the cost-effectiveness of canagliflozin 100 mg in the Slovakian setting 
from a payer perspective when compared to sitagliptin in dual therapy (add-on to 
metformin), sitagliptin in triple therapy (add-on to metformin plus sulfonylurea) and 
dapagliflozin in combination with insulin (with or without metformin). Methods: 
The IMS CORE Diabetes Model was used to evaluate the cost-effectiveness of cana-
gliflozin versus comparators using Slovakia specific data, where available. Results: 
The cost-effectiveness analyses indicated that canagliflozin 100 mg in dual therapy 
when compared with sitagliptin, was found to be cost-effective with an incremental 
cost-effectiveness ratio (ICER) of 14,930 € per QALY gained. In triple therapy when 
compared to sitagliptin, canagliflozin 100 mg was found to be cost-effective with 
an ICER of 5,251 € per QALY gained and in combination with insulin, canagliflozin 
100 mg was a dominant alternative compared to dapagliflozin with a cost saving of 
118 € per patient and higher QALYs. One-way sensitivity analyses revealed that in 
the majority of scenarios considered canagliflozin remained cost-effective in the 
dual therapy, triple therapy and add-on to insulin comparisons. ConClusions: 
Based on calculations performed using the CORE Diabetes model, canagliflozin 100 
mg appear to represent a cost-effective option for the treatment of type 2 diabetes 
in Slovakia. Canagliflozin 100 mg was found to offer greater health benefits than 
currently available alternatives and to be a cost-effective treatment option when 
used in dual and triple therapy instead of sitagliptin or as an add-on to insulin 
instead of dapagliflozin.
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objeCtives: Canagliflozin is a new oral agent for the treatment of T2DM that inhib-
its sodium-glucose co-transporter 2 (SGLT2), thereby leading to inhibition of glucose 
reabsorption and urinary glucose excretion which results in reductions in blood 
glucose, weight, and blood pressure. The purpose of this analysis was to evaluate 
the cost-effectiveness of canagliflozin vs. sitagliptin – a recommended and widely 
used dipeptidyl peptidase-4 inhibitor (DPP4) – in dual (with metformin), triple (with 
metformin + sulphonylurea) and add-on to basal insulin (with or without other 
anti-hyperglycaemic agents) therapy lines in Ireland. Methods: The Economic and 
Health Outcomes Model of T2DM (ECHO-T2DM) [using updated UKPDS 82 mortality 
and risk equations] was used to simulate lifetime outcomes and costs of patients 
on either canagliflozin (100mg, titrated to 300mg as needed to maintain glycaemic 
control) or sitagliptin 100mg. Patient characteristics and treatment effects were 
sourced from head to head randomized clinical trials for dual and triple therapy. 
For the add-on to insulin therapy simulations, treatment effects were sourced from 
a network meta-analysis. Costs were localised and inflated to 2013 euros. Utilities 
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objeCtives: To evaluate the cost-effectiveness of canagliflozin, an active inhibi-
tor of sodium glucose co-transporter – 2 (SGLT2) in dual therapy as add-on to 
metformin compared to sitagliptin and glimepiride. Canagliflozin in clinical trial 
results showed effective glucose reduction, along with other benefits in diabetes 
treatment including weight loss and SBP reduction. Cost effectiveness analyses 
were conducted in the Polish setting from a public perspective in accordance with 
guidelines of Polish HTA Agency (PolAHTA). Methods: The IMS CORE Diabetes 
Model was used to evaluate the cost-effectiveness of canagliflozin versus the 
aforementioned comparators using Polish-specific data, where available. Direct 
costs were reported in Polish zloty and an annual discount rate of 5% and 3.5% 
were applied on costs and effects respectively. Results: In dual therapy as add-on 
to metformin, canagliflozin 100 mg dominates sitagliptin with average cost savings 
of 2 811 zł and an average QALY gain of 0.06, canagliflozin 300 mg is cost effective 
option in comparison to sitagliptin with an incremental cost effectiveness ratio 
(ICER) of 45 008 zł per QALY and QALY gain of 0.09. As add-on to metformin cana-
gliflozin is a cost effectiveness option in comparison with glimepiride with ICER 
of 28 454 zł and 73 102 zł, QALY gain 0,112 QALY and 0,140 QALY for canagliflozin 
100 mg and 300 mg respectively. All results are below defined in Polish reimburse-
ment act cost-effectiveness threshold. ConClusions: These results suggest that 
adding Canagliflozin to metformin versus sitagliptin or glimepiride in patients 
inadequately controlled with metformin would be a more efficient use of health 
care resources in the Polish setting.
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objeCtives: To evaluate the cost-effectiveness of interventions aimed at decreas-
ing the number of amputations among patients with diabetic foot ulcers (DFU) in 
Russia. Methods: We have modeled the changes in the annual outcomes (minor 
and major amputations) and costs (services provided in outpatient clinics and hos-
pitals, medications, orthopedic shoes and prosthetic devices and services provided 
in case of amputation) from the perspective of public health and social care. Two 
interventions were assessed: preventive services for patients with the very high risk 
of DFU (additional outpatient visits for foot care and orthopedic shoes) and provi-
sion of care for DFU patients at hospital by multidisciplinary foot care team (MDT). 
The current number of amputations and costs among DFU patients in Russia was 
assessed on the basis of published Russian data and experts’ survey. The expected 
effectiveness of interventions was derived from the international publications. Costs 
were estimated on the basis on reimbursement rates in public medical insurance 
and social care. Results: The implementation of hospital care by MDT for cohort 
of 1000 DFU patients at the current rate of hospitalizations will require additional 
annual spending of € 532,520, and the expected annual number of major amputa-
tions will decrease by 41. The ICER for this intervention is € 12,988 per prevented 
amputation, which is almost 2 times higher than the costs associated with major 
amputation at the current moment. For the preventive services, if all patients are 
compliant, additional costs per prevented amputation are slightly lower - € 10,216, 
but also well above the costs of major amputation. ConClusions: Both interven-
tions require considerable additional budget spending. Preventive measures, if all 
the patients follow the recommendations, are more cost effective than introduction 
of hospital MDT.
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objeCtives: Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor 
used in treatment of patients with type 2 diabetes mellitus (T2DM). The objective 
is to estimate the cost-effectiveness of canagliflozin (100mg once daily and 300mg 
once daily) compared with liraglutide in combination with metformin and sulfony-
lurea (SU) for the treatment of T2DM inadequately controlled with metformin and 
SU in France. Methods: The IMS CORE Diabetes Model was used to project clinical 
and economic outcomes for patients with T2DM treated with canagliflozin or lira-
glutide, each in combination with metformin and SU. Since direct trial data were not 
available, the relative treatment effects on HbA1c, SBP and BMI for liraglutide 1.8mg 
in combination with metformin and SU were derived from a network meta-analysis 
(NMA) of treatment effects at 26 weeks. This study is limited by the absence of direct 
or indirect data on the effect of liraglutide 1.2mg in combination with metformin 
and SU, therefore the relative treatment effects on HbA1cand BMI at 26 weeks for 
liraglutide 1.2mg were estimated using the dose-response relationship from a NMA 
based on treatments in combination with metformin only. French market share 
data were used to weight the results of liraglutide 1.8mg and 1.2mg. Results: 
Canagliflozin 100mg showed cost savings when compared to treatment with lira-
glutide (1,388 € ); incremental QALYs were estimated as -0,035. Canagliflozin 300 
mg was dominant, with cost savings of 1,411 € and relatively small incremental 
QALY gain of 0.003. ConClusions: The analyses found that treatment of T2DM 
with canagliflozin 100mg or 300mg instead of liraglutide as add on to metformin 
Markov/Monte Carlo simulation techniques to describe the long-term incidence 
and progression of diabetes-related complications. It was used to simulate disease 
progression in a cohort of patients with baseline characteristics (mean age 18.6 
years, duration of diabetes 12 years, mean HbA1c 7.5%) and clinical outcomes 
(severe hypoglycaemic event rates; Quality of Life; HbA1c) taken from a recent 
randomised controlled trial (Ly et al, 2013). Local treatment and complication cost 
data was used. The main scenario considered in this cost-effectiveness analysis 
was the comparison of sensor-augmented insulin pump (SAP) with low glucose 
suspend (LGS) versus insulin pump alone (CSII). The target population was type I 
hypo-prone diabetes patients with the analysis based on a deterministic micro-
simulation of 1,000 patients, using a 5 year time horizon. Direct costs were calcu-
lated from a third-party payer perspective. Discount rates of 3% per annum were 
applied to both costs and clinical outcomes. Results: The Incremental-Cost-
Effectiveness-Ratio (ICER) for SAP+LGS (vs CSII) was € 17,893 per Quality-Adjusted-
Life-Year gained over a 5 year time horizon. Results were similar across a 1 to 10 
year time horizon. Other extensive sensitivity analyses showed the robustness 
of the results. ConClusions: Using a payer’s perspective, our analysis showed 
that SAP (w LGS) is cost-effective over a short term (5 year) time horizon in hypo-
prone Type 1 Diabetes patients in Slovakia (using a WTP threshold of 1x [€ 18,000] 
or 3x [€ 54,000] Slovakia GDP).
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objeCtives: A RCT assessed the effectiveness and costs of a home based video 
teleconsultation (HVT) setup to lower HbA1c in patients with type-2 diabetes 
against usual out-patient treatment on the hospital. The HVT equipment was 
delivered to the patients by the hospital. This analysis shows the potential incre-
mental cost-effectiveness ratio (ICER) of using a HVT setup on six-months health 
care effects and costs. Methods: The study effectiveness outcome was HbA1c 
level in %. The economic analysis was performed with a spreadsheet decision 
tree model with a Danish hospital payer’s direct cost perspective. Cost data were 
based on study measured time consumption pr. HVT, consultations at out-patient 
clinic, HVT-equipment, -subscription, -support costs, and hospital operating cost. 
Medicine costs weren’t included in the model. Model output included the cost 
of a 1 % point reduction of HbA1c, ICER, with a probabilistic sensitivity analysis 
(PSA). Two scenario analyses (SA) were made to capture costs of patient transport 
to the hospital and a future online platform, were patients can use their own 
computer/tablet to the video teleconsultations. Results: A total of 39 patients 
(mean age 62, HbA1c 8.5%) were randomized to either usual care (UC) or HVT. At 
6 months follow up the HVT group showed greater improvements from baseline 
HbA1c levels (-1.38% vs. -0.92%) and less costly (€ 199.9 vs. € 208.2) against UC. The 
base case ICER showed a potential € –17.58 saving per reduction of 1% HbA1c point. 
A PSA confirmed the ICER trends despite data uncertainties. Both SA showed 
further savings (ICER: € -67.85 and € -69.13). Compliance was 100% for HVT group 
were several planned visits were cancelled in the UC group. ConClusions: The 
present analysis shows the potential benefits of a HVT setup on 6-months health 
care cost and effects against UC. Further savings could include cost associated 
with lost work days.
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objeCtives: Sulphonylureas (SU) and insulin are used routinely in the manage-
ment of T2DM but are associated with weight gain and increased risk of hypogly-
caemia. Canagliflozin is a new insulin-independent oral glucose lowering agent 
with added benefits of weight loss, blood pressure reduction and no increased risk 
of hypoglycaemia. This analysis estimated the cost-effectiveness of canagliflozin 
compared to either SU or insulin in patients failing to achieve glycaemic control 
on metformin monotherapy in Ireland. Methods: The Economic and Health 
Outcomes Model of T2DM (ECHO-T2DM) was used to simulate the lifetime out-
comes and costs associated with canagliflozin (100mg, titrated to 300mg as needed 
to maintain glycaemic control) versus SU and versus insulin glargine. Patient 
characteristics and treatment effects for the SU comparison were sourced from a 
head-to-head randomized clinical trial vs. glimepiride. Hypoglycaemia rates were 
halved to reflect gliclazide MR (the preferred SU in Ireland). Patient characteristics 
for the insulin glargine comparison were obtained from the pooled canagliflo-
zin add-on to metformin RCTs; treatment effects were sourced from a network 
meta-analysis. Costs were localised and inflated to 2013 euros. Utilities were 
sourced from the literature. Costs and outcomes were discounted at 5% annu-
ally. Results: The incremental costs, QALY gains and ICERs associated with 
canagliflozin were € 2,404, 0.215 QALYs and € 11,191 per QALY gained, respectively, 
versus SU and € 2,352, 0.228 QALYs and € 10,305 per QALY gained, respectively, 
versus insulin glargine. Key drivers were decreased hypoglycaemia and lower 
weight-related disutility versus both comparators, as well as better HbA1c durabil-
ity versus SU. In both cases, using an acceptable Irish willingness-to-pay threshold, 
the probability of being cost-effective was in excess of 97%. Sensitivity analyses 
support the robustness of these results. ConClusions: These simulations sug-
gest that canagliflozin is a cost-effective treatment choice versus both gliclazide 
MR and insulin glargine in patients failing to control glycaemia on metformin 
alone.
